Form 4: Pacira CEO Sells Shares for Tax Obligations

Pacira BioSciences CEO Frank D. Lee disposed of 41,488 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Summary

• Frank D. Lee, Chief Executive Officer and Director of Pacira BioSciences, Inc. (PCRX), reported a transaction involving the company's common stock.
• On January 30, 2026, Mr. Lee disposed of 41,488 shares of common stock.
• The shares were disposed of at a price of $20.54 per share.
• This transaction represents shares withheld by the issuer to cover tax withholding obligations upon the vesting of a restricted stock unit award.
• Following this transaction, Mr. Lee beneficially owns 399,012.841 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a non-discretionary sale for tax purposes related to executive compensation, rather than a discretionary sale indicating a change in sentiment.

Positives

• The transaction stems from the vesting of a restricted stock unit (RSU) award, indicating successful achievement of performance or tenure milestones by the CEO.
• The sale is non-discretionary, solely for tax withholding purposes, and does not reflect a change in management's confidence in the company's future.

Negatives

• The transaction resulted in a reduction of 41,488 shares from the CEO's direct beneficial ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that tax-related sales of shares upon the vesting of restricted stock units are a routine occurrence for executives in publicly traded companies across the biotechnology and pharmaceutical sectors. This type of transaction is generally not indicative of a change in the executive's view of the company's prospects.

Comparison to Industry Standards

• This type of transaction (shares withheld for tax obligations upon RSU vesting) is a standard practice in executive compensation across industries, including biotech and pharma. For example, executives at companies like Amgen (AMGN) or Gilead Sciences (GILD) frequently report similar non-discretionary sales.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's outlook.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The transaction reported is a routine, non-discretionary sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. This type of administrative event typically does not reflect a change in the executive's confidence in the company or its future prospects, and therefore, does not warrant a change in investment recommendation. Investors should 'hold' their position based on this neutral information, awaiting more substantive operational or financial news.

Keywords

Pacira BioSciences, PCRX, Frank D. Lee, Insider Trading, Form 4, Restricted Stock Units, Tax Withholding, Executive Compensation